News | Prostate Cancer | March 09, 2017

Michigan Medicine Opens First Prostate Cancer Risk Clinic in the U.S.

The clinic will help men with genetic predisposition to prostate cancer identify and monitor their risk of the disease

Michigan Medicine, Prostate Cancer Risk Clinic, first in the U.S.

March 9, 2017 — Michigan Medicine and the University of Michigan have launched the nation’s first prostate cancer risk clinic, designed to provide individualized and structured care for men with a genetic predisposition to prostate cancer.

It is well known that women with certain hereditary genetic mutations, particularly BRCA1 and BRCA2, have an increased risk of breast cancer. But in recent years, researchers have discovered a link between some of those same genetic mutations — along with a handful of others — and aggressive prostate cancer. 

And while there are high-risk breast cancer clinics across the country providing individualized and structured care for people with a predisposition to breast cancer, there has been no corollary for men until now.

Todd Morgan, M.D., is the Michigan Medicine urological surgeon behind the new Prostate Cancer Risk Clinic.

"Even though there are high-risk breast cancer clinics all over the country and all over the world, there are, as far as we know, no other clinics like this in the United States focused on prostate cancer risk," said Morgan. "No one else has turned the corner and said, you know, wait a minute — men really need the same thing that's already available for women."

The clinic is for men who have already been tested and identified as having a hereditary mutation that predisposes them to prostate cancer. This might include mutations more traditionally associated with breast cancer or colorectal cancer.

"Typically these are men who have a strong family history of aggressive prostate cancer or a family history of prostate cancer in their dad or siblings at a really young age. Those are often signs of a potential inherited cause of that prostate cancer," Morgan said.

Having a strong family history of breast or ovarian cancer, or close relatives with a genetic predisposition to breast cancer could be another warning sign that can motivate men to be tested for genetic mutations.

"Another example would be Lynch Syndrome, which predisposes to colorectal cancer," said Morgan. "This affects men and women, and people with a family history or who have been diagnosed with colon cancer at a young age are often tested. Those guys coming to see us would likely have already been seen in our Cancer Genetics Clinic by an expert such as Dr. Elena Stoffel. Over the last 10 years we've realized that men with one of the mutations that predisposes to Lynch Syndrome are also predisposed to aggressive prostate cancer."

recent study found that 12 percent of men with metastatic cancer had genetic mutations, supporting the need for a personalized early detection program in men with these mutations.

Morgan said that prostate cancer diagnosis has been on the decline since the United States Preventative Services Task Force (USPSTF) advised against prostate-specific antigen (PSA) screening for healthy men. Since that recommendation was released five years ago, there has been a precipitous drop in the diagnosis of both low-risk, indolent prostate cancer, which probably does not need to be treated, and aggressive prostate cancer, which really does need to be diagnosed and treated.

Criticisms of the accuracy of the PSA test are fair, said Morgan. But he pointed out that there are better, more accurate tests on the market, which he will be employing at the prostate cancer risk clinic to help determine the need for a prostate biopsy, including SelectMDx, a new urine-based biomarker.

Once a man has identified, through genetic testing, that he has a genetic mutation that puts him at a higher risk for aggressive prostate cancer, he will meet with a urologic oncologist to discuss his cancer risk relative to the mutation that he has. The team at the prostate cancer risk clinic will then develop an individualized screening process for him.

"Typically, patients are going to be recommended to undergo a screening just once a year," said Morgan. "It will become part of their regular annual health routine. We're going to make sure we understand their family history. From a preventative care perspective, we're going to make sure we understand if they're doing anything that is going to increase their risk of prostate cancer. If they're smoking, overweight or not exercising, we'll discuss that with them and provide counseling options."

Blood and urine tests will be part of the annual screening. If the results indicate that a biopsy is recommended, the 15-minute outpatient procedure can take place in the clinic.

And if the biopsy suggests prostate cancer, the team at the clinic can help them walk through management options.

"Prostate cancer is the second leading cause of cancer deaths among men in the United States," said Morgan. "We now, more than ever, have an understanding of which men have cancer that needs to be treated and which men have cancer that can be closely watched. These men who have inherited mutations are much more likely to have aggressive prostate cancer. We know that treatment of aggressive prostate cancer works — it prevents death and suffering from prostate cancer. That's what this is about more than anything else: preventing death and suffering from prostate cancer."

For more information: www.mcancer.org

Related Content

Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
Exact Imaging Becomes UroGPO Imaging Partner
News | Ultrasound Imaging | August 10, 2018
Exact Imaging announced that it has become a UroGPO Imaging Partner, joining the North American urology-specific group...
SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...